Makers Laboratories

Makers Laboratories Equity

The The Equity of Makers Laboratories (506919.BO) as of Oct 28, 2026 is 729.24 M INR. In the previous year, The Equity was 705.06 M INR — a change of 3.43% (higher).

Equity

729.24 MINR

YoY

3.43%

Last updated:

In 2026, Makers Laboratories's equity was 729.24 M INR, a 3.43% increase from the 705.06 M INR equity in the previous year.

The Makers Laboratories Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
417.02 M INR
Jan 1, 2020
446.19 M INR
Jan 1, 2021
541.29 M INR
Jan 1, 2022
595.80 M INR
Jan 1, 2023
692.01 M INR
Jan 1, 2024
630.47 M INR
Jan 1, 2025
705.06 M INR
Jan 1, 2026
729.24 M INR
The Makers Laboratories Equity history
YEAREquityYoY
729.24 MINR+3.43%
705.06 MINR+11.83%
630.47 MINR-8.89%
692.01 MINR+16.15%
595.80 MINR+10.07%
541.29 MINR+21.31%
446.19 MINR+7.00%
417.02 MINR+13.25%
368.22 MINR+8.10%
340.64 MINR+29.32%
263.40 MINR+6.96%
246.25 MINR+7.52%
229.03 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Makers Laboratories Stock analysis

What does Makers Laboratories do? Makers Laboratories Ltd. generates revenue through the manufacturing and marketing of pharmaceutical products across various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). These brands target general health needs and are distributed through the Inspira retail packs division, which covers categories like acid regulatory, anthelmintics, anti-allergics, and anti-hypertensives. The Experia bulk packs division supplies bulk pharmaceutical products including amoxycillin 250 mg capsules and chloroquine phosphate 250 mg tablets to healthcare providers and pharmacies. The company's primary customers are healthcare providers and pharmacies that purchase its formulation brands and bulk packs for resale or direct patient use. The Inspira retail packs division serves retail consumers seeking over-the-counter medications for common ailments, while the Experia bulk packs division caters to institutional buyers needing bulk quantities for distribution. Makers Laboratories Ltd. focuses on the pharmaceuticals segment, offering products that address diverse health conditions through its established brand portfolio. Revenue streams are derived from both retail and bulk sales, with formulation brands driving consumer-facing sales and bulk packs supporting institutional distribution. The company's product range spans multiple therapeutic areas, ensuring consistent demand across different healthcare segments. By maintaining a diverse portfolio of branded and bulk pharmaceutical products, Makers Laboratories Ltd. effectively targets both end consumers and healthcare institutions within the Indian pharmaceutical market. Makers Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Makers Laboratories's Equity

Makers Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Makers Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Makers Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Makers Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Makers Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Makers Laboratories stock

The Equity of Makers Laboratories is 729.24 M INR in 2026.

The Equity of Makers Laboratories changed from 705.06 M INR to 729.24 M INR, representing a 3.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Makers Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Makers Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Makers Laboratories

All Key Metrics — Makers Laboratories